In the last 3 months, 4 analysts have published their opinion on BELLUS Health BLUE Stock. These analysts are typically employed by major Wall Street banks and tasked with understanding a company’s business in order to predict how a stock will trade over the coming year.
|Bullish||Rather bullish||Indifferent||a bit bearish||Bearish|
|last 30 days||0||1||0||0||0|
|2 months ago||1||0||0||0||0|
|3 months ago||0||1||0||0||0|
These 4 analysts have an average price target of $20.25 from the current price of BELLUS Health at $10.24, which implies an upside.
Below is a summary of how these 4 analysts rated BELLUS Health over the past 3 months. The higher the number of bullish ratings, the more analysts are positive on the security and the higher the number of bearish ratings, the more analysts are negative on the security
This average price target has increased by 28.57% over the past month.
If you want to follow the news and performance of small cap stocks, you can start by following them here.
Analysts work in banking and financial systems and typically specialize in reporting on stocks or defined sectors. Analysts can attend company conference calls and meetings, research company financials, and communicate with insiders to issue “analyst notes” for stocks. Analysts typically rate each stock once a quarter.
Some analysts publish their forecasts for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and industry analysts are also human and only offer their opinions to investors.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.